Catenion’s systematic review of R&D productivity and corporate growth metrics shows that size correlates negatively with performance from a certain point onward. (See[A#2014800090], in which we reviewed 10-year cumulative R&D spending adjusted for costs of M&A versus value created in the pipeline and products launched over the last five years, plus growth in topline, EBITDA, and market cap for the top 30 public pharma companies.)
In our survey, all top performers are mid-size companies; mostly with a biotech heritage, such as Gilead Sciences Inc., Biogen Inc., or Celgene Corp. The ‘Sweet Spot’...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?